Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for the treatment of cancer. The company aims to improve the lives of patients through the discovery and development of novel small molecule therapies.
EVENTS PER QUARTER · HOVER FOR EMPLOYEE COUNTS
Exelixis, Inc., a Bay Area biotech company valued at $10 billion, has laid off 130 workers as part of a cost-cutting strategy. This decision reflects the company's efforts to streamline operations amid financial pressures. The layoffs occurred recently and are aimed at improving the company's financial health. Exelixis has not specified which departments were affected by these job cuts. The move highlights the challenges faced by biotech firms in the current economic climate.
Exelixis, Inc. has laid off 130 employees as part of a strategic shake-up within the company. This decision comes amidst the company's recent market successes, indicating a shift in operational focus. The layoffs are part of a broader restructuring effort aimed at optimizing resources and aligning with future business goals. While the specific departments affected were not disclosed, this move reflects Exelixis' commitment to adapting to market demands and enhancing its competitive position in the biotech industry.
No one has shared a story from Exelixis yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.